Consulting
Whitecase
Full Credential Description
Adelis faced the challenge of maximizing the value of its investment in Europa Biosite, a specialist distributor of life science research reagents, after acquiring the company in 2021. The primary issue was to effectively execute an international buy-and-build strategy to enhance Europa Biosites market position and operational footprint across Europe and North America. This involved navigating the complexities of integrating multiple acquisitions and expanding the companys reach in a competitive market. To address these challenges, Adelis implemented a strategic plan that included acquiring five companies over four years, which significantly bolstered Europa Biosites capabilities and market presence. This tailored solution not only expanded the companys portfolio but also established it as a leading distributor in the life sciences sector, offering innovative products to over 60,000 researchers. The successful execution of this strategy culminated in the sale of Adeliss majority stake in Europa Biosite to EQT Healthcare Growth, marking a significant milestone in the companys growth trajectory. As a result of these efforts, Europa Biosite achieved a pan-European commercial footprint and managed a portfolio of more than ten million SKUs, thereby enhancing its service offerings to thousands of life science researchers. This strategic growth and the subsequent sale underscore the successful transformation of Europa Biosite into a key player in the life sciences distribution market, demonstrating the effectiveness of Adeliss investment strategy and operational execution.